Argonaut Capital Management’s AbbVie ABBV Stock Holding History

Argonaut Capital Management’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	$544K	Hold	10,000	–	–	1.83%	20
2015 Q2	$672K	Buy	+10,000	New	+$653K	1.94%	19

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Argonaut Capital Management's ABBV Position: Q3 2015 in Review

Argonaut Capital Management held its AbbVie (ABBV) position steady in Q3 2015 at 10,000 shares worth $544K. The position accounts for 1.83% of the portfolio, ranked #20.

Argonaut Capital Management first reported a position in ABBV in Q2 2015 and has held it in 2 quarters since. The position peaked at $672K in Q2 2015. 1,604 funds tracked by Wall St. Rank hold ABBV as of Q3 2015.

Argonaut Capital Management held 10,000 shares of AbbVie worth $544K as of Q3 2015.
Argonaut Capital Management left its AbbVie share count unchanged in Q3 2015.
AbbVie made up 1.83% of Argonaut Capital Management's portfolio in Q3 2015, its #20 holding.
Argonaut Capital Management first reported a position in AbbVie in Q2 2015 and has held it in 2 quarters since.
Argonaut Capital Management's AbbVie position peaked at $672K in Q2 2015.
1,604 funds tracked by Wall St. Rank held AbbVie as of Q3 2015.

Based on Argonaut Capital Management's 13F filing for Q3 2015, filed 16 Nov 2015.